Chen Chu

Dr. Chen Chu


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2008 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
CCChen Chu
Chen Chu
EMEduardo MénDez
Eduardo MénDez
JHJohn Houck
John Houck
WFWenhong Fan
Wenhong Fan
PLPawadee Lohavanichbutr
Pawadee Lohavanichbutr
LZLue Ping Zhao
Lue Ping Zhao
Oral squamous cell carcinoma (OSCC) is associated with substantial mortality and morbidity. To identify potential biomarkers for the early detection of invasive OSCC, we compared the gene expressions of incident primary OSCC, oral dysplasia, and clinically normal oral tissue from surgical patients without head and neck cancer or preneoplastic oral lesions (controls), using Affymetrix U133 2.0 Plus arrays. We identified 131 differentially expressed probe sets using a training set of 119 OSCC patients and 35 controls. Forward and stepwise logistic regression analyses identified 10 successive combinations of genes which expression differentiated OSCC from controls. The best model included LAMC2, encoding laminin-γ2 chain, and COL4A1, encoding collagen, type IV α1 chain. Subsequent modeling without these two markers showed that COL1A1, encoding collagen, type I α1 chain, and PADI1, encoding peptidyl arginine deiminase, type 1, could also distinguish OSCC from controls. We validated these two models using an internal independent testing set of 48 invasive OSCC and 10 controls and an external testing set of 42 head and neck squamous cell carcinoma cases and 14 controls (GEO GSE6791), with sensitivity and specificity above 95%. These two models were also able to distinguish dysplasia (n = 17) from control (n = 35) tissue. Differential expression of these four genes was confirmed by quantitative reverse transcription-PCR. If confirmed in larger studies, the proposed models may hold promise for monitoring local recurrence at surgical margins and the development of second primary oral cancer in patients with OSCC. (Cancer Epidemiol Biomarkers Prev 2008;17(8):2152–62)

1 March 2013 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PLPawadee Lohavanichbutr
Pawadee Lohavanichbutr
EMEduardo Méndez
Eduardo Méndez
FHF. Christopher Holsinger
F. Christopher Holsinger
TRTessa C. Rue
Tessa C. Rue
YZYuzheng Zhang
Yuzheng Zhang
CCChen Chu
Chen Chu
Purpose: To identify a prognostic gene signature for patients with human papilloma virus (HPV)–negative oral squamous cell carcinomas (OSCC). Experimental Design: Two gene expression datasets were used: a training dataset from the Fred Hutchinson Cancer Research Center (FHCRC, Seattle, WA; n = 97) and a validation dataset from the MD Anderson Cancer Center (MDACC, Houston, TX; n = 71). We applied L1/L2-penalized Cox regression models to the FHCRC data on the 131-gene signature previously identified to be prognostic in patients with OSCCs to identify a prognostic model specific for patients with high-risk HPV-negative OSCCs. The models were tested with the MDACC dataset using a receiver operating characteristic (ROC) analysis. Results: A 13-gene model was identified as the best predictor of HPV-negative OSCC-specific survival in the training dataset. The risk score for each patient in the validation dataset was calculated from this model and dichotomized at the median. The estimated 2-year mortality (±SE) of patients with high-risk scores was 47.1% (±9.24%) compared with 6.35% (±4.42) for patients with low-risk scores. ROC analyses showed that the areas under the curve for the age, gender, and treatment modality-adjusted models with risk score [0.78; 95% confidence interval (CI), 0.74–0.86] and risk score plus tumor stage (0.79; 95% CI, 0.75–0.87) were substantially higher than for the model with tumor stage (0.54; 95% CI, 0.48–0.62). Conclusions: We identified and validated a 13-gene signature that is considerably better than tumor stage in predicting survival of patients with HPV-negative OSCCs. Further evaluation of this gene signature as a prognostic marker in other populations of patients with HPV-negative OSCC is warranted. Clin Cancer Res; 19(5); 1197–203. ©2012 AACR.

1 January 2018 in Menopause
Verified
Journal Article
Closed access
CCCarolyn J. Crandall
Carolyn J. Crandall
KHKathleen M. Hovey
Kathleen M. Hovey
CAChristopher A. Andrews
Christopher A. Andrews
RCRowan T. Chlebowski
Rowan T. Chlebowski
MSMarcia L. Stefanick
Marcia L. Stefanick
JMJoAnn E. MD Manson
JoAnn E. MD Manson
Objective: To determine the association between use of vaginal estrogen and risk of a global index event (GIE), defined as time to first occurrence of coronary heart disease (CHD), invasive breast cancer, stroke, pulmonary embolism, hip fracture, colorectal cancer, endometrial cancer, or death from any cause. Methods: For this prospective observational cohort study, we used data from participants of the Women's Health Initiative Observational Study, who were recruited at 40 US clinical centers, aged 50 to 79 years at baseline and did not use systemic estrogen therapy during follow-up (n = 45,663, median follow-up 7.2 years). We collected data regarding incident CHD, invasive breast cancer, stroke, pulmonary embolism, hip fracture, colorectal cancer, endometrial cancer, death, and self-reported use of vaginal estrogen (cream, tablet). We used Cox proportional-hazards regression models to adjust for covariates. Results: Among women with an intact uterus, the risks of stroke, invasive breast cancer, colorectal cancer, endometrial cancer, and pulmonary embolism/deep vein thrombosis were not significantly different between vaginal estrogen users and nonusers, whereas the risks of CHD, fracture, all-cause mortality, and GIE were lower in users than in nonusers (GIE adjusted hazard ratio 0.68, 95% confidence interval 0.55-0.86). Among hysterectomized women, the risks of each of the individual GIE components and of the overall GIE were not significantly different in users versus nonusers of vaginal estrogen (GIE adjusted hazard ratio 0.94, 95% confidence interval 0.70-1.26). Conclusions: The risks of cardiovascular disease and cancer were not elevated among postmenopausal women using vaginal estrogens, providing reassurance about the safety of treatment.

23 September 2020 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
WZWen Zhou
Wen Zhou
GLGeoffrey Liu
Geoffrey Liu
RHRayjean J. Hung
Rayjean J. Hung
PHPhilip C. Haycock
Philip C. Haycock
MAMelinda C. Aldrich
Melinda C. Aldrich
CAChristopher I. Amos
Christopher I. Amos

18 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
LFLu Feng
Lu Feng
JHJohn R. Houck
John R. Houck
PLPawadee Lohavanichbutr
Pawadee Lohavanichbutr
CCChen Chu
Chen Chu
Transcriptome analysis reveals differentially expressed lncRNAs between oral squamous cell carcinoma and healthy oral mucosa Transcriptome analysis reveals differentially expressed lncRNAs between oral squamous cell carcinoma and healthy oral mucosa

16 February 2009 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
PLPawadee Lohavanichbutr
Pawadee Lohavanichbutr
JHJohn Houck
John Houck
WFWenhong Fan
Wenhong Fan
BYBevan Yueh
Bevan Yueh
EMEduardo Mendez
Eduardo Mendez
CCChen Chu
Chen Chu
Oral cavity and oropharyngeal squamous cell carcinomas (OSCCs) constitute a major public health burden worldwide. Approximately 400 000 new cases of OSCC were diagnosed in 2002, and approximately 200 000 patients died of these cancers.1 The major risk factors for OSCC are cigarette smoking, alcohol consumption, and betel quid chewing. The evidence for human papillomavirus (HPV) as a potential etiologic agent in OSCC was first reported in 1983, when the presence of HPV antigen was shown in oral cancer specimens.2 Subsequent publications showed an association between infection with high-risk types of HPV and OSCC risk.3-6Molecular and epidemiologic studies strongly suggest that HPV-positive OSCC is a distinctive disease entity that differs from HPV-negative OSCC in molecular, histopathologic, and prognostic characteristics,7-10 HPV-positive OSCC (1) being less frequently associated with p53 mutations, (2) occurring primarily in the oropharynx, (3) tending to be poorly differentiated and basaloid subtypes, and (4) having a more favorable disease outcome.7 To understand the molecular mechanisms underlying these 2 entities of OSCC, we examined genomewide gene expression profiles of HPV-positive and HPV-negative OSCC.